Amgen Inc. (AMGN.VI)

Compare

275.15

-3.10

(-1.11%)

At close: April 4 at 5:32:16 PM GMT+2

3 Dividend Stocks to Buy and Hold for the Next Decade

What should investors do when stocks are tanking over the short term? Three Motley Fool contributors think they've found great dividend stocks to own for the long term that pay you to wait for better days. Here's why they picked AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), and Eli Lilly (NYSE: LLY).

Motley Fool 8 hours ago

ABBV

AMGN

LLY
2 Dividend Stocks to Buy Hand Over Fist in April

This stands to reason, as nearly every stage of drug development and marketing is resource- and capital-intensive, and as a result, cash can be in short supply. Let's take a look at two outliers with dividend policies that have looked especially attractive lately -- pharmaceutical companies Amgen (NASDAQ: AMGN) and AbbVie (NYSE: ABBV). Amgen's involvement in the high-demand obesity drugs race has attracted attention recently, but the pharmaceutical sector star has been on the radar of clever investors for years.

Motley Fool yesterday

AMGN

ABBV
Amgen (NasdaqGS:AMGN) Gains FDA Approval For UPLIZNA In Treating IgG4-Related Disease

Amgen (NasdaqGS:AMGN) experienced a significant 18.62% price increase over the last quarter, coinciding with the recent FDA approval of UPLIZNA for treating Immunoglobulin G4-related disease (IgG4-RD). This approval, alongside the Breakthrough Therapy Designation granted by the FDA, reflects high unmet medical needs being addressed, which could have positively influenced investor sentiment. Despite broader market declines, including a 5% drop in the Nasdaq Composite due to trade tensions,...

Simply Wall St. 2 days ago

AMGN
AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication

The FDA approves Amgen's Uplizna as the first and only drug for the treatment of immunoglobulin G4-related disease.

Zacks 2 days ago

AMGN
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts

Amgen (AMGN) concluded the recent trading session at $310.09, signifying a +1.44% move from its prior day's close.

Zacks 2 days ago

AMGN

^GSPC
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday

As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. Two areas that suffered relatively light damage, however, were pharmaceuticals and biotech. Compared to the S&P 500's (SNPINDEX: ^GSPC) 4.8% tumble, Catalyst Pharmaceuticals' (NASDAQ: CPRX) 1.5% drop was mild, as was Veeva Systems' (NYSE: VEEV) 2% slide.

Motley Fool 2 days ago

AMGN

^GSPC
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE

Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD). IgG4-RD is a chronic and debilitating immune-mediated inflammatory condition that can affect multiple organs. The FDA granted Breakthrough Therapy Designation to UPLIZNA for the treatment of IgG4-RD, recognizing the high unmet medical need in this serious condition and the medicine's potential

PR Newswire 2 days ago

AMGN
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder

(Reuters) -The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said on Thursday. The drug, also known as inebilizumab, has now become the first FDA-approved treatment for Immunoglobulin G4-related disease (IgG4-RD), a rare condition in which an overactive immune system can lead to inflammation and scarring in various organs, including the pancreas, liver and kidneys. "By removing or depleting these B cells throughout the body, both in the circulating blood and in the tissue, there's a chance for Uplizna to confer a real benefit," said Jay Bradner, Amgen's head of research and development.

Reuters 2 days ago

AMGN
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).

StockStory 3 days ago

AMGN

BMRN

MRNA
Got $5,000? These 3 Nasdaq Stocks Are Dirt Cheap Buys Right Now

As of Monday, the Nasdaq Composite index had tumbled more than 11% since the start of the year. On the contrary -- this can be an optimal time to score some deals and investments you can hang on to for the long haul. If you've got $5,000 you can afford to invest in the stock market today, three stocks you'll want to consider loading up on right now are Amgen (NASDAQ: AMGN), PayPal (NASDAQ: PYPL), and Baidu (NASDAQ: BIDU).

Motley Fool 3 days ago

BIDU

COMP

PYPL
GILD or AMGN: Which Is the Better Value Stock Right Now?

GILD vs. AMGN: Which Stock Is the Better Value Option?

Zacks 5 days ago

AMGN

GILD
Nvidia, Other Techs Hurt Dow Jones, But These Names Outperformed In Q1

The overseers of the Dow Jones Industrial Average might regret adding Nvidia to the index. Since it joined the Dow industrials on Nov. 7, Nvidia stock is down nearly 30%. Nvidia stock is on track for its worst month since September 2022, when it lost nearly 20%, according to Dow Jones Market Data.

Investor's Business Daily 5 days ago

AMGN

JNJ

NVDA
These biotech names aren't facing 'huge concern' from tariffs

Trump's upcoming tariffs has the potential to bring biopharma manufacturing to the US, which could impact companies with overseas production. Jefferies managing director Michael Yee joins Market Domination Overtime to discuss how tariffs could impact the biotech sector, emphasizing Vertex (VRTX), Amgen (AMGN), and Gilead (GILD) as some of his top large-cap picks in the sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.

Yahoo Finance Video 5 days ago

GILD

VRTX

AMGN
Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing

Amgen (AMGN) concluded the recent trading session at $311.55, signifying a +1.5% move from its prior day's close.

Zacks 5 days ago

AMGN
RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar

Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.

Zacks 6 days ago

JNJ

AMGN
2 Surefire Dividend Stocks That Could Pay You for Life

Dividend investing is an excellent strategy for (at least) two reasons. Here are two companies that can pull it off: Amgen (NASDAQ: AMGN) and Coca-Cola (NYSE: KO). Amgen paid its first dividend in 2011.

Motley Fool 9 days ago

KO

AMGN
2 Large-Cap Stocks with Solid Fundamentals and 1 to Turn Down

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.

StockStory 9 days ago

TGT

AMGN

AZO
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks 9 days ago

AMGN
Which Dow Jones Stock Is Cheaper, Amgen or Merck?

Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an impressive 21% year to date. Meanwhile, shares of its pharmaceutical rival Merck (NYSE: MRK) have lagged, down 8% in the same period. Amgen shareholders are celebrating, but have you wondered which stock is cheaper right now?

Motley Fool 9 days ago

AMGN
Trump Weighs Tariffs on Pharma in Ireland. What It Means for Amgen, Gilead.

Jefferies analysts singled out the stocks that will be affected the most and the least by potential import taxes.

Barrons.com 10 days ago

AMGN

VRTX

Performance Overview

Return	AMGN.VI	S&P 500 (^GSPC)
YTD	+10.57%	-13.73%
1-Year	+12.69%	-1.42%
3-Year	+36.40%	+10.72%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Amgen Inc. (AMGN.VI)

3 Dividend Stocks to Buy and Hold for the Next Decade

2 Dividend Stocks to Buy Hand Over Fist in April

Amgen (NasdaqGS:AMGN) Gains FDA Approval For UPLIZNA In Treating IgG4-Related Disease

AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication

Amgen (AMGN) Rises As Market Takes a Dip: Key Facts

Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday

UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE

US FDA approves Amgen's Uplizna as first treatment for rare immune disorder

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

Got $5,000? These 3 Nasdaq Stocks Are Dirt Cheap Buys Right Now

GILD or AMGN: Which Is the Better Value Stock Right Now?

Nvidia, Other Techs Hurt Dow Jones, But These Names Outperformed In Q1

These biotech names aren't facing 'huge concern' from tariffs

Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing

RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar

2 Surefire Dividend Stocks That Could Pay You for Life

2 Large-Cap Stocks with Solid Fundamentals and 1 to Turn Down

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Which Dow Jones Stock Is Cheaper, Amgen or Merck?

Trump Weighs Tariffs on Pharma in Ireland. What It Means for Amgen, Gilead.

Performance Overview